{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-106534","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.707720+00:00","generated_at":"2026-05-17T16:01:23.544400+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FibroGen Q2 loss narrows to $13.7M; China sale to AstraZeneca now ~$210M, cash runway into 2028","bullets":["Net loss from continuing ops $13.7M ($3.38/sh) vs $47.1M loss ($11.79/sh) in Q2 2024; revenue $1.3M.","Sale of FibroGen China to AstraZeneca now ~$210M total consideration (up $50M), including ~$125M net cash; close expected Q3 2025.","Cash runway extended into 2028 upon China sale close; Q2 consolidated cash $142.1M.","Agreed with FDA on pivotal Phase 3 design for roxadustat in LR-MDS with high transfusion burden; protocol filing Q4 2025.","Phase 2 monotherapy trial of FG-3246 in mCRPC expected to start Q3 2025; combo data from UCSF study expected Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-106534","json":"https://secwatch.observer/filing/0000950170-25-106534.json","markdown":"https://secwatch.observer/filing/0000950170-25-106534.md","text":"https://secwatch.observer/filing/0000950170-25-106534.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017025106534/0000950170-25-106534-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017025106534/fgen-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:01:23.544400+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}